title: Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate.
abstract: We provide a full account of the discovery of the (E)-9,10-dehydro derivatives of 12,13-desoxyepothilone B (dEpoB), a new class of antitumor agents with promising in vivo preclinical properties. The compounds, which are to date not available by modification of any of the naturally occurring epothilones, were discovered through total chemical synthesis. We describe how our investigations of ring-closing metathesis reactions in epothilone settings led to the first and second generation syntheses of (E)-9,10-dehydro-12,13-desoxyepothilone congener 6. With further modifications, the synthesis was applied to reach a 26-trifluoro derivative compound (see compound 7). To conduct such studies and in anticipation of future development needs, the total synthesis which led to the initial discovery of compound 7 was simplified significantly. The total synthesis methodology used to reach compound 7 was then applied to reach more readily formulated compounds, bearing hydroxy and amino functionality on the 21-position (see compounds 45, 62, and 63). Following extensive in vitro evaluations of these new congeners, compound 7 was nominated for in vivo evaluations in xenograft models. The data provided herein demonstrate a promising therapeutic efficacy, activity against large tumors, nonrelapseability, and oral activity. These results have identified compound 7 as a particularly promising compound for clinical development. The excellent, totally synthetic, route to 7 makes such a program quite feasible.
authors.affiliation: Contribution from the Laboratory for Bioorganic Chemistry, Preclinical Pharmacology Core Facility, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA.
authors.forename: Alexey
authors.initials: A
authors.lastname: Rivkin
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Yoshimura
authors.forename: Ana E
authors.initials: AE
authors.lastname: Gabarda
authors.forename: Young Shin
authors.initials: YS
authors.lastname: Cho
authors.forename: Ting-Chao
authors.initials: TC
authors.lastname: Chou
authors.forename: Huajin
authors.initials: H
authors.lastname: Dong
authors.forename: Samuel J
authors.initials: SJ
authors.lastname: Danishefsky
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D034261:Epothilones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D051379:Mice; D009161:Mycobacterium / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
chemical_list: C493047:26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B; D000970:Antineoplastic Agents; D034261:Epothilones